FAFrancesca Amoroso

Francesca Amoroso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesca Amoroso has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Engineering Rapid Payload Release Rate in 1,6‐Elimination Processes of Self‐Immolative Linkers

    by Albert Marten Schulte, Gülbahar Bozan, Francesca Amoroso, Bart Cornelissen, Wiktor Szymanski

    Stimuli‐responsive prodrugs form the foundation of targeted medicine. These compounds, once activated at the site of interest, release their bioactive payload, often through elimination from self‐immolative linkers (SILs). However, payload release rates from activated SILs can vary widely depending on the SIL's (electronic) structure. Low release rates do not compete with diffusion of the activated prodrug from the target site, which compromises the spatial resolution and diminishes the practical utility. Here we report a new strategy to engineer the payload release rate from SILs through the introduction of cation‐stabilizing substituents, which yields an up to 10 4 ‐fold improvement in rate constant compared to the reference SIL. Relating the DFT‐computed stabilities of an ion pair intermediate with the first order rate constants for self‐immolation revealed a strong correlation, providing a robust rational basis for our strategy. Furthermore, we discovered that lipophilicity of the SIL‐payload conjugate is a key, and hitherto overlooked, factor affecting the rate, based on which we propose a new model for the overall payload release reaction. Lastly, we show the practical utility of our strategy, through demonstrating the superiority of our SILs in releasing the anticancer drug palbociclib and studying radiation‐dependent enzyme inhibition and cell‐cycle alteration.

  • Open Access

    Engineering Rapid Payload Release Rate in 1,6‐Elimination Processes of Self‐Immolative Linkers

    by Albert Marten Schulte, Gülbahar Bozan, Francesca Amoroso, Bart Cornelissen, Wiktor Szymanski

    Stimuli‐responsive prodrugs form the foundation of targeted medicine. These compounds, once activated at the site of interest, release their bioactive payload, often through elimination from self‐immolative linkers (SILs). However, payload release rates from activated SILs can vary widely depending on the SIL's (electronic) structure. Low release rates do not compete with diffusion of the activated prodrug from the target site, which compromises the spatial resolution and diminishes the practical utility. Here we report a new strategy to engineer the payload release rate from SILs through the introduction of cation‐stabilizing substituents, which yields an up to 10 4 ‐fold improvement in rate constant compared to the reference SIL. Relating the DFT‐computed stabilities of an ion pair intermediate with the first order rate constants for self‐immolation revealed a strong correlation, providing a robust rational basis for our strategy. Furthermore, we discovered that lipophilicity of the SIL‐payload conjugate is a key, and hitherto overlooked, factor affecting the rate, based on which we propose a new model for the overall payload release reaction. Lastly, we show the practical utility of our strategy, through demonstrating the superiority of our SILs in releasing the anticancer drug palbociclib and studying radiation‐dependent enzyme inhibition and cell‐cycle alteration.

  • Open Access

    IRF7 impacts on prostate cancer cell survival in response to radiation

    by Adam Pickard, Francesca Amoroso, Kelsey McCulloch, Andrew Erickson, Ashwin Sachdeva, Rebecca Steele, Debayan Mukherjee, Margaret Dellett, Jonathan McComb, Laura McCaffery, et al.

    Understanding the impact of radiotherapy on the evolution of treatment resistant prostate cancer is critical for selecting effective treatment combinations. Whilst activation of Type 1 interferon signalling is a hallmark of how cells respond to viral infection, in cancer cells, multiple stresses are known to activate this same response. In this study we have evaluated for the first time the changes in the interferon response induced by culturing prostate cancer cells under sphere- forming conditions and following irradiation. We report a conserved upregulated transcript profile for both conditions that is strongly associated with therapeutic resistance and cell survival in vitro and in vivo. The profile includes and is regulated by the Type 1 interferon master regulator IRF7 which, when depleted, delays tumour re-growth following irradiation. We immuno-stained two independent prostate cohorts for IRF7 and found that increased expression, particularly in cases with low PTEN expression, correlated with poor prognosis. To more comprehensively characterise the impact of IRF7 and radiation on cells, RNA-Seq was performed on IRF7 knockdown cells at different radiation doses. We identified a number of biological processes that were IRF7-dependent, including the formation of stem-like cell populations and also therapeutic vulnerabilities. For example, irradiation sensitised surviving cells to either a combination of an IKKε/TBK1 and a MEK inhibitor or treatment with an inhibitor of IDO1, an IRF7- dependent gene. Translationally our work suggests that IRF7 expression can be used to stratify patients who may not benefit from receiving radiotherapy alone but rather may benefit from treatment combinations. In two cohorts treated with radical intent, strong IRF7 staining was associated with disease-specific death implicating this pathway as a convergence point for therapeutic resistance in prostate and potentially other cancer types.

  • Genetics of lipid metabolism in prostate cancer

    by Ninu Poulose, Francesca Amoroso, Rebecca E. Steele, Reema Singh, Chee Wee Ong, Ian G. Mills


  • Open Access

    P2×7 targeting inhibits growth of human mesothelioma

    by Francesca Amoroso, Erica Salaro, Simonetta Falzoni, Paola Chiozzi, Anna Lisa Giuliani, Giorgio Cavallesco, Pio Maniscalco, Andrea Puozzo, Ilaria Bononi, Fernanda Martini, et al.

    P2X7 targeting inhibits growth of human mesothelioma


  • Open Access

    Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death

    by Erica Salaro, Alessia Rambaldi, Simonetta Falzoni, Francesca Saveria Amoroso, Alessia Franceschini, Alba Clara Sarti, Massimo Bonora, Francesco Cavazzini, Gian Matteo Rigolin, Maria Ciccone, et al.

    Lymphocyte growth and differentiation are modulated by extracellular nucleotides and P2 receptors. We previously showed that the P2X7 receptor (P2X7R or P2RX7) is overexpressed in circulating lymphocytes from chronic lymphocytic leukemia (CLL) patients. In the present study we investigated the P2X7R/NLRP3 inflammasome axis in lymphocytes from a cohort of 23 CLL patients. P2X7R, ASC and NLRP3 were investigated by Western blot, PCR and transfection techniques. P2X7R was overexpressed and correlated with chromosome 12 trisomy in CLL patients. ASC mRNA and protein were also overexpressed. On the contrary, NLRP3 was dramatically down-modulated in CLL lymphocytes relative to lymphocytes from healthy donors. To further investigate the correlation between P2X7R, NLRP3 and cell growth, NLRP3 was silenced in THP-1 cells, a leukemic cell line that natively expresses both NLRP3 and P2X7R. NLRP3 silencing enhanced P2X7R expression and promoted growth. On the contrary, NLRP3 overexpression caused accelerated apoptosis. The P2X7R was also up-modulated in hematopoietic cells from NLRP3-KO mice. In conclusion, we show that NLRP3 down-modulation stimulates P2X7R expression and promotes growth, while NLRP3 overexpression inhibits cell proliferation and stimulates apoptosis. These findings suggest that NLRP3 is a negative regulator of growth and point to a role of the P2X7R/NLRP3 axis in CLL.


  • Emerging Roles of P2X Receptors in Cancer

    by Elena Adinolfi, Marina Capece, Francesca Amoroso, Elena Marchi, Alessia Franceschini

    Tumor microenvironment composition strongly conditions cancer growth and progression, acting not only at cancer itself but also modifying its interactions with immune, endothelial and nervous cells. Extracellular ATP and its receptors recently gained increasing attention in the oncological field. ATP accumulates in cancer milieu through spontaneous release, tumor necrosis or chemotherapy exerting a trophic activity on cancer cells, modulating the cross talk among tumor, and surrounding tissues. Accordingly, ATP gated P2X receptors emerged as central players in tumor development, invasion, progression and related symptoms. Indeed, P2X receptors are expressed and are functional not only on tumor cells but also in immune-infiltrate and nearby neurons. In this review, we summarize recent findings on P2X receptors role in tumor cell differentiation, bioenergetics, angiogenesis, metastasis and associated pain, giving an outline of the potential anti-neoplastic activity of receptor agonists and antagonists.


  • Open Access

    Trophic Activity of Human P2X7 Receptor Isoforms A and B in Osteosarcoma

    by Anna Lisa Giuliani, Davide Colognesi, Tiziana Ricco, Carlotta Roncato, Marina Capece, Francesca Amoroso, Qi Guang Wang, Elena De Marchi, Allison Gartland, Francesco Di Virgilio, et al.

    The P2X7 receptor (P2X7R) is attracting increasing attention for its involvement in cancer. Several recent studies have shown a crucial role of P2X7R in tumour cell growth, angiogenesis and invasiveness. In this study, we investigated the role of the two known human P2X7R functional splice variants, the full length P2X7RA and the truncated P2X7RB, in osteosarcoma cell growth. Immunohistochemical analysis of a tissue array of human osteosarcomas showed that forty-four, of a total fifty-four tumours (81.4%), stained positive for both P2X7RA and B, thirty-one (57.4%) were positive using an anti-P2X7RA antibody, whereas fifteen of the total number (27.7%) expressed only P2X7RB. P2X7RB positive tumours showed increased cell density, at the expense of extracellular matrix. The human osteosarcoma cell line Te85, which lacks endogenous P2X7R expression, was stably transfected with either P2X7RA, P2X7RB, or both. Receptor expression was a powerful stimulus for cell growth, the most efficient growth-promoting isoform being P2X7RB alone. Growth stimulation was matched by increased Ca2+ mobilization and enhanced NFATc1 activity. Te85 P2X7RA+B cells presented pore formation as well as spontaneous extracellular ATP release. The ATP release was sustained in all clones by P2X7R agonist (BzATP) and reduced following P2X7R antagonist (A740003) application. BzATP also increased cell growth and activated NFATc1 levels. On the other hand cyclosporin A (CSA) affected both NFATc1 activation and cell growth, definitively linking P2X7R stimulation to NFATc1 and cell proliferation. All transfected clones also showed reduced RANK-L expression, and an overall decreased RANK-L/OPG ratio. Mineralization was increased in Te85 P2X7RA+B cells while it was significantly diminished in Te85 P2X7RB clones, in agreement with immunohistochemical results. In summary, our data show that the majority of human osteosarcomas express P2X7RA and B and suggest that expression of either isoform is differently coupled to cell growth or activity.


  • Open Access

    P2X7 Receptor Function in Bone-Related Cancer

    by Elena Adinolfi, Francesca Amoroso, Anna Lisa Giuliani

    Modulation of tumor microenvironment by different mediators is central in determining neoplastic formation and progression. Among these molecules extracellular ATP is emerging as a good candidate in promoting cell growth, neovascularization, tumor-host interactions, and metastatization. This paper summarizes recent findings on expression and function of P2X7 receptor for extracellular ATP in primary and metastatic bone cancers. Search of mRNA expression microchip databases and literature analysis demonstrate a high expression of P2X7 in primary bone tumors as well as in other malignancies such as multiple myeloma, neuroblastoma, breast, and prostate cancer. Evidence that P2X7 triggers NFATc1, PI3K/Akt, ROCK, and VEGF pathways in osteoblasts promoting either primary tumor development or osteoblastic lesions is also reported. Moreover, P2X7 receptor is involved in osteoclast differentiation, RANKL expression, matrix metalloproteases and cathepsin secretion thus promoting bone resorption and osteolytic lesions. Taken together these data point to a pivotal role for the P2X7 receptor in bone cancer biology.


  • Open Access

    The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells

    by Catrin Schult, Meike Dahlhaus, Sabine Ruck, Mandy Sawitzky, Francesca Amoroso, Sandra Lange, Daniela Etro, Aenne Glass, Georg Fuellen, Sonja Boldt, et al.

    Background: Targeted therapy approaches have been successfully introduced into the treatment of several cancers. The multikinase inhibitor Sorafenib has antitumor activity in solid tumors and its effects on acute lymphoblastic leukemia (ALL) cells are still unclear.Methods: ALL cell lines (SEM, RS4;11 and Jurkat) were treated with Sorafenib alone or in combination with cytarabine, doxorubicin or RAD001. Cell count, apoptosis and necrosis rates, cell cycle distribution, protein phosphorylation and metabolic activity were determined.Results: Sorafenib inhibited the proliferation of ALL cells by cell cycle arrest accompanied by down-regulation of CyclinD3 and CDK4. Furthermore, Sorafenib initiated apoptosis by cleavage of caspases 3, 7 and PARP. Apoptosis and necrosis rates increased significantly with most pronounced effects after 96 h. Antiproliferative effects of Sorafenib were associated with a decreased phosphorylation of Akt (Ser473 and Thr308), FoxO3A (Thr32) and 4EBP-1 (Ser65 and Thr70) as early as 0.5 h after treatment. Synergistic effects were seen when Sorafenib was combined with other cytotoxic drugs or a mTOR inhibitor emphasizing the Sorafenib effect.Conclusion: Sorafenib displays significant antileukemic activityin vitroby inducing cell cycle arrest and apoptosis. Furthermore, it influences PI3K/Akt/mTOR signaling in ALL cells.